Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertensionheart failure and percutenous coronary interventions (PCI).

News | Heart Valve Technology | March 29, 2020

March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing...

Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020
Feature | Heart Valve Technology | March 29, 2020 | Dave Fornell, Editor

March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve...

POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020

March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing...

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020

March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to...

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020

March 28, 2020 — People with symptomatic...

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

News | Heart Valve Technology | March 25, 2020

 

March 25, 2020 — CroiValve announced the successful first human use of its Duo Tricuspid Coaptation Valve...

Medicare, CMS, calls for cancelling or postponing all elective or non-essential medical procedures, test and surgeries due to COVID-19. #COVID19 #SARcov2 #coronavirus #cardiology
Feature | Coronavirus (COVID-19) | March 20, 2020 | Dave Fornell, Editor
Philips Healthcare's new Fiber Optic RealShape (FORS) technology creates real-time 3-D imaging of anatomy and devices inside the body using light, rather than X-rays. FORS uses light traveling through hair-thin fiber optics inside special FORS enabled catheter and guidewires.

Philips Healthcare's new Fiber Optic RealShape (FORS) technology creates real-time 3-D imaging of anatomy and devices inside the body using light, rather than X-rays. FORS uses light traveling through hair-thin fiber optics inside special FORS enabled catheter and guidewires. 

Feature | Angiography | March 12, 2020 | Dave Fornell, Editor

Philips is working on a prototype cath lab angiographic imaging system that might be able to replace the current X-...

ACC issues document outlining COVID-19 Implications For Patients With Underlying Cardiovascular Conditions. The COVID-19 mortality rate for patients cardiovascular disease is 10.5 percent based of data from Chinese hospitals since the outbreak. COVID-19 fatality rates for patients with comorbidities are higher than the average population, but cardiac patients had the highest death rate. #COVID19 #coronavirus #2019nCoV #SARS‐CoV‐2

The COVID-19 mortality rate for patients cardiovascular disease is 10.5 percent based of data from Chinese hospitals since the outbreak. COVID-19 fatality rates for patients with comorbidities are higher than the average population, but cardiac patients had the highest death rate.

Feature | Coronavirus (COVID-19) | March 09, 2020

March 9, 2020 — The American College of Cardiology (ACC) is...

Overlay Init